A clinical and immunological study of a myasthenia gravis patient treated with infliximab

Acta Neurologica Scandinavica

Volumn 115, Issue 4, 2007, Pages 279-283

  Kakoulidou, M ^a   Bjelak, S ^a   Pirskanen, R ^a   Lefvert, A K ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Case study; Infliximab; Myasthenia gravis

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA DR ANTIGEN; IMMUNOGLOBULIN G; INFLIXIMAB; METHYLPREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE;

ADULT; CASE REPORT; CD4+ T LYMPHOCYTE; DRUG MEGADOSE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; LIVER DISEASE; MALE; MUSCLE FATIGUE; MUSCLE FUNCTION; MYASTHENIA GRAVIS; PSYCHOSIS; RADIOIMMUNOASSAY; REVIEW; THYMOMA;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MUSCLE STRENGTH; MYASTHENIA GRAVIS; RECOVERY OF FUNCTION; TREATMENT OUTCOME;

EID: 33947359333     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00778.x     Document Type: Review

References (18)

1. ROMI F, GILHUS NE, AARLI JA. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol Scand 2005;111:134-41.
2. MATUSEVICIUS D, NAVIKAS V, PALASIK W, PIRSKANEN R, FREDRIKSON S, LINK H. Tumor necrosis factor-alpha, lymphotoxin, interleukin (IL)-6, IL-10, IL- 12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis. J Neuroimmunol 1996;71:191-8.
3. AHLBERG RE, PIRSKANEN R, LEFVERT AK. Defective T lymphocyte function in nonthymectomized patients with myasthenia gravis. Clin Immunol Immunopathol 1991;60:93-105.
4. HUANG DR, PIRSKANEN R, MATELL G, LEFVERT AK. Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis. J Neuroimmunol 1999;94:165-71.
5. CHRISTADOSS P, GOLUSZKO E. Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. J Neuroimmunol 2002;122:186-90.
6. GOLUSZKO E, DENG C, POUSSIN MA, CHRISTADOSS P. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J Neuroimmunol 2002;122:85-93.
7. ROWIN J, MERIGGIOLI MN, TUZUN E, LEURGANS S, CHRISTADOSS P. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 2004;63:2390-2392.
8. COHEN-KAMINSKY S, JACQUES Y, AIME C, SAFAR D, MOREL E, BERRIH-AKNIN S. Follow-up of soluble interleukin-2 receptor levels after thymectomy in patients with myasthenia gravis. Clin Immunol Immunopathol 1992;62:190-8.
9. TESAR V, JELINKOVA E, JIRSA M JR, BAKOSOVA M, PITHA P, CHABOVA V. Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange. Blood Purif 2000;18:115-20.
10. WONG CK, LIT LC, TAM LS, LI EK, LAM CW. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44:989-94.
11. JARETZKI A III, BAROHN RJ, ERNSTO RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
12. LEFVERT AK, BERGSTROM K, MATELL G, OSTERMAN PO, PIRSKANEN R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry 1978;41:394-403.
13. REICHERT T, DEBRUYERE M, DENEYS V, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol 1991;60:190-208.
14. MPOFU S, FATIMA F, MOOTS RJ. Anti-TNF-alpha therapies: they are all the same (aren't they?). Rheumatology (Oxford) 2005;44:271-3.
15. SIDDIQUI MA, SCOTT LJ. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 2005;65:2179-208.
16. GRUBER R, REITER C, RIETHMULLER G. Triple immunofluorescence flow cytometry, using whole blood, of CD4+ and CD8+ lymphocytes expressing CD45RO and CD45RA. J Immunol Methods 1993;163:173- 9.
17. MORIMOTO C, LETVIN NL, DISTASO JA, ALDRICH WR, SCHLOSSMAN SF. The isolation and characterization of the human suppressor inducer T cell subset. J Immunol 1985;134:1508- 15.
18. VUILLIER F, SCOTT-ALGARA D, DIGHIERO G. Extensive analysis of lymphocyte subsets in normal subjects by three-color immunofluorescence. Nouv Rev Fr Hematol 1991;33:31-8.